Bryce Point Capital LLC Invests $488,000 in Hologic, Inc. (NASDAQ:HOLX)

Bryce Point Capital LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,763 shares of the medical equipment provider’s stock, valued at approximately $488,000.

Other large investors also recently bought and sold shares of the company. General Partner Inc. bought a new stake in shares of Hologic in the fourth quarter worth approximately $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HOLX shares. Wolfe Research began coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $84.62.

Hologic Trading Down 1.3 %

Hologic stock opened at $60.86 on Friday. Hologic, Inc. has a 1 year low of $59.06 and a 1 year high of $84.67. The firm’s 50 day moving average price is $64.30 and its 200-day moving average price is $72.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market cap of $13.66 billion, a P/E ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.